STADA and Church & Dwight Enter into an Agreement to Launch Consumer Healthcare Brands in Eurasia

STADA is introducing Church & Dwight’s CHC and FMCG brands in nine¹ countries across the Eurasian region. Georgia is the first market in the region, where HERO and TROJAN products have been commercially available since April 1, 2026.

In line with its commitment to being a trusted partner, STADA is significantly strengthening its consumer healthcare portfolio in the Eurasian region with well-established brands such as Hero, Trojan, and Batiste.

Kuanish Ospanov, Vice President, Eurasia Region, STADA: “The agreement with Church & Dwight is further proof of STADA Eurasia’s ability to be a partner of choice. We believe in the Eurasian markets and see significant potential for further growth in the CHC segment.”

Almaty, April 20, 2026 — STADA is strengthening its presence in Eurasia by entering into a strategic agreement with Church & Dwight (C&D), the owner of a portfolio of globally recognized brands. Under the agreement, STADA will undertake the launch, promotion, and distribution of a number of C&D’s popular consumer brands across nine countries in the Eurasian region.

Georgia is the first country where STADA has introduced C&D products. In the remaining countries covered by the agreement, C&D products will be launched throughout 2026.

The agreement includes six well-established brands. The key brands are Batiste (dry shampoo), Hero (acne treatment patches), and Trojan (condoms). These popular brands will effectively complement STADA’s local CHC portfolio and strengthen its offering in the consumer healthcare segment.

STADA is responsible for local marketing and the promotion of products through traditional pharmacies, retail, and online sales channels.

“The agreement with Church & Dwight is further proof that STADA Eurasia is a partner of choice. I am particularly proud that our Eurasia division is the first among all STADA markets to introduce C&D brands. We believe in the potential of the Eurasian markets and see significant opportunities for further development of the CHC segment,” said Kuanish Ospanov, Vice President, Eurasia Region, STADA.

Christos Gyouras, Regional Director, Church & Dwight, said:

“We are pleased to introduce our iconic brands to new consumers across the Eurasian countries through our partnership with STADA. We are confident that STADA will successfully bring our leading brands to this promising and dynamic market.”

It is also expected that, in the future, the agreement may be expanded to include additional existing and new C&D brands.

¹ Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, and Moldova. Note: Not all brands included in the transaction will be represented in individual markets.

About STADA

STADA Arzneimittel AG, headquartered in Bad Vilbel, Germany, pursues a strategy based on three core segments: Consumer Healthcare products, generics, and specialty pharmaceuticals. The company’s products are sold in more than 100 countries worldwide.

In the 2025 financial year, STADA achieved adjusted group revenue of €4.3 billion and adjusted earnings before interest, taxes, depreciation, and amortization (adj. cc EBITDA) of €961 million. As of December 31, 2025, the company employed 11,749 people worldwide.

About Church & Dwight

Church & Dwight Co., Inc. (NYSE: CHD), founded in 1846 and headquartered in Ewing, New Jersey, is a company with approximately $6.1 billion in sales and is a member of the S&P 500 index.

The company manufactures and markets a broad range of personal care, household, and specialty products under well-known brands such as ARM & HAMMER®, TROJAN®, OXICLEAN®, FIRST RESPONSE®, NAIR®, ORAJEL®, BATISTE®, WATERPIK®, ZICAM®, THERABREATH/THE BREATH CO®, and HERO®.